Rate Shows / BiotechTV - News Your browser cannot play this audio here. This plays from the publisher's own server. We do not host a copy.
Open at the source
Not rated yet Not interested: Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1 Clear rating for Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1
Save for later In Library Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1 Description CEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company's pipeline progress.
Back to BiotechTV - News · Report a problem